Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...

More information: Bo Shi et al, Heavy-chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in ...

Ono Pharmaceutical has entered a partnership agreement with Epsilon Molecular Engineering (EME) to advance the drug discovery of the variable heavy domain of heavy chain (VHH) antibodies to ...

By these arrangements, each of the two arms of the antibody includes one light chain and one heavy chain, with the variable regions at the tips of the Y arms defining antigen specificity.

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced ...

The antibody molecule in particular has been ... the reassembly of naturally occurring genes encoding the heavy- and light-chain domains from either immune 1,2 or nonimmune B-cell sources 3 ...

It is a fully human monoclonal antibody targeting TSLP, generated from the two heavy chains and two light chains (H2L2) Harbour Mice ® platform. It inhibits the TSLP-mediated signaling pathway by ...

The HCAb Harbour Mice® platform is revolutionizing antibody development by producing unique heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering ...